Visión generalGráficoPerfilEstadísticas claveBalance generalNoticias
Derivados
TraderScreen

ORION CLASS B/  FI0009014377  /

Euronext Milan
17/10/2024  10:23:51 Diferencia - Volumen Bid9:59:55 Ask9:59:55 Capitalización de mecado Dividendo A. P/E Ratio
47.600EUR - 636
Volumen de negocios: 29,822.160		 -Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 4.77 mil millonesEUR 3.63% 28.96
GlobeNewswire 17/07 Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation...
GlobeNewswire 01/07 Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive ...
GlobeNewswire 03/06 Orion is developing the Finnish life science industry in a unique collaboration project
GlobeNewswire 26/01 Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
GlobeNewswire 08/01 Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ...
GlobeNewswire 05/01 Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patient...
GlobeNewswire 27/12/2023 NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
GlobeNewswire 15/11/2023 Orion Research Foundation grants EUR 1,112,000 for research in 2024
GlobeNewswire 24/03/2022 Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
GlobeNewswire 18/02/2022 Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
GlobeNewswire 17/02/2022 Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall surviva...
GlobeNewswire 03/12/2021 ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets...
GlobeNewswire 09/06/2021 Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality...
GlobeNewswire 09/12/2019 Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
GlobeNewswire 31/07/2019 U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant pro...
GlobeNewswire 19/06/2019 1,767 Orion Corporation A shares converted into B shares
GlobeNewswire 11/06/2019 Change in Orion Corporation's holding of treasury shares
GlobeNewswire 06/06/2019 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...
GlobeNewswire 03/06/2019 Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Sprint Corp...
GlobeNewswire 31/05/2019 2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented
GlobeNewswire 30/05/2019 ORION NOTICE: Rosen, a Widely Recognized Law Firm, Reminds Orion Group Holdings, Inc. Investors of I...
GlobeNewswire 30/05/2019 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...
GlobeNewswire 22/05/2019 S DEADLINE ALERT: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit A...
GlobeNewswire 22/05/2019 ORN JUNE 10 DEADLINE:  Pawar Law Group Reminds Investors of Deadline in Securities Class Action Laws...
GlobeNewswire 22/05/2019 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ori...